Results 241 to 250 of about 230,151 (306)

Enhancer‐dependent gene regulation in space, time, and malignancies

open access: yesInternational Journal of Cancer, Volume 158, Issue 2, Page 357-367, 15 January 2026.
Abstract Control of cell‐type‐specific gene activation requires the coordinated activity of distal regulatory elements, including enhancers, whose inputs must be temporally integrated. Dysregulation of this regulatory capacity, such as aberrant usage of enhancers, can result in malignant transformation of cells.
Belinda Blum   +2 more
wiley   +1 more source

Global burden of acute lymphoblastic leukemia following the COVID-19 pandemic. [PDF]

open access: yesAnn Hematol
Fan H   +6 more
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

open access: yesInternational Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner   +7 more
wiley   +1 more source

Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia. [PDF]

open access: yesHemasphere
Kirchhoff H   +10 more
europepmc   +1 more source

Reduced cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia

open access: green, 2013
Emily S. Tonorezos   +9 more
openalex   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia—A Retrospective, Dual‐Center Study

open access: yesAmerican Journal of Hematology, Volume 101, Issue 1, Page 16-25, January 2026.
ABSTRACT Survival outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have improved with modern frontline therapies and minimal residual disease (MRD)‐guided strategies. As a result, allogeneic hematopoietic cell transplantation (HCT) is increasingly deferred in first remission (CR1) and used in the relapsed setting.
Oren Pasvolsky   +24 more
wiley   +1 more source

Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations

open access: yesAmerican Journal of Hematology, Volume 101, Issue 1, Page 41-55, January 2026.
ABSTRACT Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma. The success of asparaginase‐containing regimens has led to trials of pediatric/pediatric‐inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations with acute ...
Ibrahim Aldoss   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy